Kornimate/medical-research-clean huggingface dataset:
to determine if chromium nicotinate supplementation will improve insulin resistance in hiv patients with metabolic abnormalities

Conditions: HIV Infections

Summary: in hiv patients, fasting insulin levels decrease with chromium supplementation. this study is to determine if chromium nicotinate supplementation at 400ug/day for 16 weeks will improve insulin resistance in hiv patients with metabolic abnormalities.

this study is a randomized, double-blind, placebo-controlled, crossover study where patients will be supplemented for 16 weeks with either chromium nicotinate 400 ug/day or placebo and then crossover to the opposite treatment for another 16 weeks. each soft gel capsule of chromium contains 200ug of chromium and patients will take 1 capsule twice a day or its placebo. placebo contains di-calcium phosphate in a soft gel capsule and its appearance is similar to the chromium capsules.

Eligibility criteria:
inclusion criteria: * hiv documented patients will be considered for the study if they have at least one abnormality with respect to fasting blood glucose, tg, total or hdl cholesterol. normal fasting glucose is defined as \< 6.1 mmol/l. hypertriglyceridemia is defined as concentrations above 2.0 mmol/l on the basis of reports of increased risk of cardiac disease. hypercholesterolemia is defined as concentrations above 5.5 mmol/l and a low hdl-cholesterol concentration as less than 0.9 mmol/l. * patients will need to be on a stable drug regimen for at least 8 weeks and not taking any chromium supplement or chromium-containing multivitamins 4 weeks prior to and during the study period. patients can stay on their hypoglycemic or lipid-lowering medications and the required dosage will be monitored. exclusion criteria: * patients will be excluded if there is concomitant acute infection or malignancy.

Keywords: hiv blood sugar > 6.1 mmol/l triglycerides > 2 mmol/l total cholesterol > 5.5 mmol/l or hdl < 0.9 mmol/l
metabolic adaptations in response to high intensity interval training in obese adults

Conditions: Glucose Intolerance

Summary: the overall objectives are to: 1. assess mechanisms underlying hiit-induced improvements in insulin resistance at the whole-body, tissue, and cellular levels. 2. systematically compare different hiit regimens to help identify effective "doses" of hiit that may be optimal for improving metabolic health in obese adults. 3. assess the ability/willingness of obese subjects to adhere to a long-term hiit program. findings from these studies will greatly expand knowledge about the effects of hiit on metabolic health, and will provide valuable information for development of programs aimed at maximizing key metabolic benefits of exercise.

if subjects are eligible for the study, they will be randomized into one of four different exercise training groups. before training (and twice after 3 months of training) subjects will participate in a "clinical study" in which they will be required to stay overnight in the hospital. during the clinical study, the research team will perform a series of metabolic tests. before and after the 3 months of training, the research team will assess subjects "free-living" 24h blood sugar control using a continuous glucose monitor (cgm). the research team will measure several other relevant clinical markers (e.g., whole body and regional body fat assessments \[dual energy x-ray absorptiometry (dexa) and magnetic resonance imager (mri)\], hepatic lipid accumulation \[mri analysis\], blood lipid profile, resting metabolic rate, glycated hemoglobin \[hemoglobin a1c\]). after the first 3 months of training, adherence to the subjects assigned training program will be tracked for the next 9 months (1 year of training in total). one year after initiating a training program, subjects will be asked to return to the clinic for a quick follow-up visit where the research team will complete some standard clinical assessments (e.g., body weight, body composition, blood pressure, and a blood sample).

Eligibility criteria:
inclusion criteria: * age: 18-40 * body mass index: 30-40 kg/m2 * waist circumference: 88-98cm for women and 100-110cm for men * glucose intolerant (i.e., 2h glucose concentration during a screening oral glucose tolerance test (ogtt)= 140-199mg/dl * no regularly planned exercise/physical activity * women must have regularly occurring menses and must be premenopausal exclusion criteria: * ekg abnormalities as assessed by the cardiologist on the research team * evidence/history of cardiovascular or metabolic disease * medications known to affect lipid or glucose metabolism * pregnant or lactating * tobacco or e-cigarette use
cldn18.2 targeting nanobody probe for pet imaging in solid tumors

Conditions: Solid Tumor

Summary: the objective of the study is to construct a noninvasive approach 68ga-acn376 pet/ct to detect the cldn18.2 expression of tumor lesions in patients with solid tumors and to identify patients benefiting from cldn18.2 targeting treatment.


Eligibility criteria:
inclusion criteria: * 1. aged \>18 years old; ecog 0 or 1; * 2. patients with solid tumors; * 3. has at least one measurable target lesion according to response evaluation criteria in solid tumors (recist v1.1); * 4. life expectancy \>=12 weeks. exclusion criteria: * 1. significant hepatic or renal dysfunction; * 2. is pregnant or ready to pregnant; * 3. cannot keep their states for half an hour; * 4. refusal to join the clinical study; * 5. suffering from claustrophobia or other mental diseases; * 6. any other situation that researchers think it is not suitable to participate in the experiment.
premature atherosclerosis in systemic lupus erythematosus

Conditions: SLE; Atherosclerosis

Summary: patients with sle have increased rates of atherosclerosis, while the risk factors for atherosclerosis in those patients were not fully revealed. this study is an observational study to investigate the natural process and risk factors for atherosclerosis based on a chinese sle cohort. carotid intima media thickness (cimt) and brachial-ankle pulse wave velocity (bapwv) will be measured for each patient at baseline and 5-year follow-up. blood tests including cholesterol levels, fasting plasma glucose levels and etc. will also be performed.

accelerated atherosclerosis is a major complication of systemic lupus erythematosus (sle), and it leads to increased cardiovascular morbidity and mortality in patients with sle. prevention and intervention of premature atherosclerosis is beneficial for prognosis and survival of patients with sle. the primary aim of this study was to investigate the natural progress of carotid intima media thickness (cimt) in 5 years, and examine the risk factors for progression of cimt and atherosclerotic plaques based on a chinese sle cohort. the secondary aims of the study were to investigate progression of brachial-ankle pulse wave velocity (bapwv), and to examine the risk factors for increasing bapwv in patients with sle. based on sample size calculation, 440 patients who meet the eligibility criteria will be enrolled in this study. all patients will be enrolled from peking union medical college hospital. after informed consent is obtained, the patients will be comprehensively evaluated from demographic characteristics, medical history, clinical assessments, laboratory tests results, cimt and bapwv at baseline and 5-year follow-up. descriptive analysis, univariate analysis, and multivariate analysis will be used to analyze the correlation between potential risk factors and cimt/bapwv.

Eligibility criteria:
inclusion criteria: * age≥18 years * fulfillment of clinical classification criteria of sle (four or more 1997 american college of rheumatology classification criteria) * provision of signed written informed consent exclusion criteria: * clinically overt coronary artery disease * a history of cardiovascular disease (previous stroke, heart failure, myocardial infarction, angina, or symptomatic pad) * malignancy * pregnant/lactating women

Keywords: sle atherosclerosis carotid intima media thickness brachial-ankle pulse wave velocity risk factors cohort
clinical effects of internet assisted pulmonary rehabilitation of covid-2019 pneumonia patients after discharge

Conditions: COVID-2019 Pneumonia; Pulmonary Rehabilitation

Summary: the noval coronavirus disease 2019 (covid-19) would cause physical and psychological dysfunctions in infected patients. we expect that an intelligence-based remote pulmonary rehabilitation scheme could improve patients' health status after hospital discharge. the intelligence-based remote pulmonary rehabilitation program is designed in a real-world and prospective manner, aiming to evaluate the efficacy of rehabilitation among 200 patients in the epicenter of china (wuhan city) according to their varied adherence. an eight-week rehabilitation scheme, including two weeks for physicians and physiotherapists remotely guided training, and six weeks for patient self-management, will be addressed. the primary outcome of current study is six-minute walking distance and lung function, and secondly respiratory muscle strength, physical fitness assessment, symptoms and quality of life, etc. will also be assessed. recruited patients will be followed up at week 2, 4, 8 after enrollment and at month 1, 3, 6, 12 after the rehabilitation training completed, respectively. the study has been approved by the ethics committee of china-japan friendship hospital and three participating centers in wuhan city.


Eligibility criteria:
inclusion criteria: * patients diagnosed as covid-19 pneumonia according to the chinese diagnostic criteria (trial 7th edition), aged 20 years or above; * patients who did not participate in any other rehabilitation training scheme; * patients who did not participate in any other intervention clinical trials; * patients who signed the informed consent and were able to adhere to a long-term follow-up for at least one year. exclusion criteria: * pregnant women; * patients with previous mental disorders or undergoing mental health treatment; * patients with previous personality disorder, intelligence disorder, brain injury or brain disease; * patients with serious cardiovascular, cerebrovascular, neuromuscular and other systemic diseases or other diseases affecting physical activity; * patients with tumors and underwent treatment. one will be considered as withdrawal if consent is revoked, lost to follow-up, or unable to take the pulmonary rehabilitation scheme due to severe exacerbation, comorbidities, injury or trauma, etc.
digital rehabilitation environment augmenting medical system

Conditions: Delirium

Summary: d.r.e.a.m.s. will assess an immersive digital reality-augmenting system in reducing the occurrence of cognitive, behavioral, and emotional consequences of critical illness and environmental exposures that are risk factors for the development of delirium.

the purpose of digital rehabilitation environment augmenting medical system (d.r.e.a.m.s.) is to research the feasibility and clinical potential of an immersive digital reality-augmenting system in reducing the occurrence of cognitive, behavioral, and emotional consequences of critical illness (e.g. pain, anxiety and insomnia) and environmental exposures (noise \& light) that are risk factors for the development of delirium, a common and devastating complication in the intensive care unit (icu).

Eligibility criteria:
inclusion criteria: * all patients ≥ 18 years admitted to university of florida (uf) health shands hospital who do not have a positive confusion assessment method (cam) score, including icu patients. exclusion criteria: the study team will exclude patients if: * their anticipated icu stay is less than one day * patient is intubated and cannot communicate. * age: \< 18 years * patient with recent (within 6 months) neuro-vascular event, intra-cranial surgery, and/or acute neurological condition as primary icu admission reason * baseline cognitive impairment (e.g., advanced dementia) * patients who are unable to wear or use the dreams equipment

Keywords: delirium prevention virtual reality vr
clinical evaluation of the bioli iol delivery system (bioli-d)

Conditions: Cataract Senile

Summary: cataract surgery is one of the most frequent surgeries carried out in the world. after cataract extraction an intraocular lens (iol) is implanted in order to compensate for the crystalline lens power and correct patient's vision. in order to allow cataract extraction and iol insertion, during the surgery a small incision is performed by the surgeon. this incision is performed using surgical knives, and a smaller incisión is associated with less postoperatory inflammation, faster corneal wound healing, and faster visual recovery. several studies reported the importance of smaller incisions to reduce the risk of surgically induced astigmatism. in order to implant the iol through this small incision, the iol must be preloaded in a injector that allows introducing the iol eficiently and consistently. the manual injector bioli manufactured by ast products (model d), ce approved, is designed specifically to allow the iol insertion safely, precisely, and controllably. among the main characteristics of this delivery system is its design to minimize the incision size widening while inserting the iol. the present retrospective study aims to provide more information with regards to the clinical efficacy of the bioli-d delivery system for the implantation of the trifocal asqelio tflio130c iol in patients submitted to cataract surgery. this will be assessed by analyzing the change in incision size after iol implantation and the incidence of adverse events during and after the procedure.


Eligibility criteria:
inclusion criteria: * patients 50 years or older submitted to cataract surgery and implanted with asqelio trifocal tflio130c iol using the bioli-d delivery system. * patients submitted to bilateral cataract surgery. * transparent ocular media, other than the bilateral cataract. exclusion criteria: * preoperatory corneal astigmatism greater than 0.75d * corneal surgery or trauma prior to cataract surgery irregular cornea * choroidal hemorrhage * microftalmos severe corneal dystrophy * uncontrolled or medically controlled glaucoma * clinically significant macular changes * concomitant ocular disease * not age-related cataract * severe optic nerve atrophy * diabetic retinopathy * proliferative diabetic retinopathy * amblyopia * extremelly shallow anterior chamber * severe chronic uveitis * rubella * mature/dense cataract difficulting fundas assessment preoperatively * prior retinal detachment * concurrent participation in another investigation with medication or clinical devices
home telemonitoring system for patients with heart failure

Conditions: Heart Failure

Summary: this randomized controlled trial compares a home telemonitoring system (hts) versus usual care during a 90 days follow-up of heart failure (hf) ambulatory patients, in order to evaluate if the use of the hts improves self-care and treatment adherence. the study was reviewed and approved by the methodological committee and by the research ethics committee from the provincial health system, according to the declaration of helsinki. written informed consent was obtained before randomization.


Eligibility criteria:
inclusion criteria: * were over 18 years with a primary diagnosis of hf, * had been hospitalized at least once time as a consequence of a hf decompensation, * had a smartphone, * had access to wifi, * had access to a weight scale and to a blood-pressure monitor exclusion criteria: * illiterate patients, * had learning difficulties, * had a cognitive impairment sufficient to interfere with the use of the telemonitoring system, or had a severe depression that could interfere with their quality of life perception.
eus-fni for nonfunctional pancreatic neuroendocrine tumors

Conditions: Nonfunctional Pancreatic Neuroendocrine Tumor; Pancreatic Neuroendocrine Tumor; Endoscopic Ultrasound

Summary: the current study aims to access the feasibility, safety, and efficacy of eus-fni for nonfunctional pnets

the management of nonfunctional pancreatic neuroendocrine tumors (nf-pnets) remains controversial. in general, surgical resection is the standard treatment for nf-pnets. however, the incidence of postoperative adverse events of surgical resection is relatively high. recently, several studies have revealed that endoscopic ultrasonography (eus)-guided fine-needle injection (eus-fni) with ethanol or lauromacrogol may offer an effective treatment for pnets. therefore, a multicenter prospective study is being conducted to further identify the efficacy and safety of eus-fni for nf-pnets.

Eligibility criteria:
inclusion criteria: 1. patients with nf-pnets are evaluated by cytology or immunohistochemistry. 2. patients who refuse surgery or observation. 3. patients who have given their fully informed consent. exclusion criteria: 1. patients who are not suitable for eus-fni. 2. patients who have poor conditions including blood coagulation dysfunction, mental disorders, and mild or severe cardiorespiratory.

Keywords: nonfunctional pancreatic neuroendocrine tumor endoscopic ultrasonography-guided fine-needle injection ablation endoscopic ultrasonography
roxadustat combined with sacubitril valsartan sodium tablets in the treatment of cardiorenal anemia syndrome

Conditions: Cardio-Renal Syndrome

Summary: a randomized and parallel controlled trial design of comparing the new treatment group of roxadustat combined with sacubitril valsartan sodium tablets with the traditional treatment group of recombinant human erythropoietin (epo) combined with acei or arb in chinese patients with cardiorenal anemia syndrome.


Eligibility criteria:
inclusion criteria: * diagnosed as regular dialysis patients with cardiorenal anemia syndrome * hemoglobin 60-110g / l (twice with an interval of at least 4 days); * volunteered to participate exclusion criteria: * anemia caused by diseases other than ckd * malignant tumors * active liver disease * rheumatic immune diseases in active stage * hereditary or idiopathic angioedema * systolic blood pressure≥180 mmhg;diastolic blood pressure≥110 mmhg * acute myocardial infarction and unstable angina pectoris * severe parathyroidism * active peptic ulcer * taking aliskiren * mental disease * alcohol and drug abuse * allergy to test drugs
smoking cessation behavioral treatment study

Conditions: Tobacco Use Disorder

Summary: the purpose of this study is to evaluate the effectiveness of two behavioral interventions on smoking behavior - mindfulness-oriented recovery enhancement (more) and cognitive behavioral therapy (cbt). more is a behavioral therapy that integrates mindfulness training to modify reward processes. cbt is a therapy designed to help individuals understand how their thoughts and feelings influence their behaviors.


Eligibility criteria:
inclusion criteria: * age 18 and up * english fluency as demonstrated in providing informed consent and the ability to independently follow directions in completing assigned assessments and tasks * functional vision (with corrective lenses as needed) to complete assigned assessments and tasks * current nicotine dependent smoker with a minimum smoking history of 2 years * interest in quitting smoking exclusion criteria: * use of psychotropic (e.g. antiepileptic) medications in the past month * positive urine drug screen * presence of an untreated medical illness * current or past psychosis * history of major neurological illness or head injury resulting in loss of consciousness * and contraindication to mri, including claustrophobia * among females, positive urine pregnancy test * inability or unwillingness of subject to give informed consent
enhancing sleep duration: effects on children's eating and activity behaviors

Conditions: Sleep; Obesity

Summary: the proposed study aims to determine whether an intervention to increase sleep in school-age children is associated with positive changes in eating, activity behaviors and zbmi. one hundred four children 8-11 years old who sleep 9 ½ hours or less per night will be randomly assigned to 1 of 2 conditions: 1) optimize sleep (increase tib by 1 ½ hours/night to produce a change in sleep duration of approximately 40 minutes/night), or 2) control (no change in sleep). families of children in the optimize sleep group will be taught effective behavioral strategies that have been shown to improve sleep duration. at baseline, 2-week and 2-month follow-up, the following will be gathered: sleep duration (measured by actigraphy), food intake (measured by 3 days of 24-hour recall), activity level (measured by accelerometry), the relative reinforcing value (rrv) of food (measured using a validated experimental paradigm), and measured child height and weight.


Eligibility criteria:
inclusion criteria: * age 8-11 years old * bmi for age and gender \> 10th percentile (but no greater than 100% overweight) * sleep 9.5 hours or less nightly * attend elementary school * like at least 1 food used in the reinforcement paradigm * able to understand and complete the reinforcement paradigm exclusion criteria: * existence of a diagnosable parasomnia, sleep disordered breathing * medical or psychiatric condition that could influence sleep or weight * inability to complete study materials, including diagnosed disabilities * dietary restrictions/allergies to foods used in the study that preclude them from study participation

Keywords: sleep obesity children eating behaviors activity
ripple mapping for epicardial mapping of brugada syndrome

Conditions: Brugada Syndrome

Summary: whether a mapping algorithm "ripple-mapping" is able to rapidly identify the areas of long-duration multicomponent electrograms which constitute the targets for ablation for an automated strategy remains to be assessed.


Eligibility criteria:
inclusion criteria: * brugada syndrome patients requiring ablation exclusion criteria: * patients not able to consent
biomarkers in urine samples from patients with wilms tumor

Conditions: Kidney Cancer

Summary: rationale: studying samples of urine from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer. purpose: this clinical trial studies biomarkers in urine from patients with wilms tumor.

objectives: * to validate the prognostic performance of specific-candidate wilms tumor markers by measuring their urinary concentration using enzyme-linked immunosorbent assays (elisas) in urine specimens collected at diagnosis from 50 patients with favorable histology wilms tumor who relapsed and 50 patients who did not relapse. outline: urine specimens are analyzed using enzyme-linked immunosorbent assays (elisas) for biomarkers.

Eligibility criteria:
disease characteristics: * urine specimens collected at diagnosis will be selected from patients with stage ii-iii wilms tumors, with both local and non-local sites of disease relapse * clinical patient information (urinalysis/macro, age, gender, congenital defects/syndromes, comorbidities, tumor stage, size, pathology, therapy, outcome) available patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: stage ii wilms tumor stage iii wilms tumor recurrent wilms tumor and other childhood kidney tumors